Tyler E. Wagner

Tyler E. Wagner

Auto-generated profile, based on publicly available information

Tyler E. Wagner

Department of Biomedical Research, Nference, Inc., Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
HDHilary M. DuBrock
Hilary M. DuBrock
TWTyler E. Wagner
Tyler E. Wagner
KCKatherine Carlson
Katherine Carlson
CCCorinne L. Carpenter
Corinne L. Carpenter
SASamir Awasthi
Samir Awasthi
VSVenky Soundararajan
Venky Soundararajan
Background: Early diagnosis of pulmonary hypertension (PH) is critical for effective treatment and management. We aimed to develop and externally validate an artificial intelligence algorithm that could serve as a PH screening tool, based on analysis of a standard 12-lead ECG.Methods: The PH Early Detection Algorithm (PH-EDA) is a convolutional neural network developed using retrospective ECG voltage–time data, with patients classified as “PH-likely” or “PH-unlikely” (controls) based on right heart catheterisation or echocardiography. In total, 39 823 PH-likely patients and 219 404 control patients from Mayo Clinic were randomly split into training (48%), validation (12%) and test (40%) sets. ECGs taken within 1 month of PH diagnosis (diagnostic dataset) were used to train the PH-EDA at Mayo Clinic. Performance was tested on diagnostic ECGs within the test sets from Mayo Clinic (n=16 175/87 998 PH-likely/controls) and Vanderbilt University Medical Center (VUMC; n=6045/24 256 PH-likely/controls). In addition, performance was tested on ECGs taken 6–18 months (pre-emptive dataset), and up to 5 years prior to a PH diagnosis at both sites.Results: Performance testing yielded an area under the receiver operating characteristic curve (AUC) of 0.92 and 0.88 in the diagnostic test sets at Mayo Clinic and VUMC, respectively, and 0.86 and 0.81, respectively, in the pre-emptive test sets. The AUC remained a minimum of 0.79 at Mayo Clinic and 0.73 at VUMC up to 5 years before diagnosis.Conclusion: The PH-EDA can detect PH at diagnosis and 6–18 months prior, demonstrating the potential to accelerate diagnosis and management of this debilitating disease.

1 May 2025 in JCO Oncology Practice
Verified
Journal Article
Open access
TSTyler B. Sandahl
Tyler B. Sandahl
SSScott A A Soefje
Scott A A Soefje
RFRafael Fonseca
Rafael Fonseca
Sikander AilawadhiSikander Ailawadhi
Sikander Ailawadhi
RPRicardo Parrondo
Ricardo Parrondo
SKShaji Kumar
Shaji Kumar
PURPOSE: Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS: This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS: At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION: Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.

1 April 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
HBHannah Barman
Hannah Barman
SVSriram Venkateswaran
Sriram Venkateswaran
ASAntonio Del Santo
Antonio Del Santo
UYUnice Yoo
Unice Yoo
ESEli Silvert
Eli Silvert
RMRajat Mohindra
Rajat Mohindra
PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in the real-world data setting is critical for characterizing the benefit/risk profile of ICI therapies beyond the clinical trial population. Diagnosis codes, such as International Classification of Diseases codes, do not comprehensively illustrate a patient's care journey and offer no insight into drug-irAE causality. This study aims to capture the relationship between ICIs and irAEs more accurately by using augmented curation (AC), a natural language processing–based innovation, on unstructured data in electronic health records. METHODS: In a cohort of 9,290 patients treated with ICIs at Mayo Clinic from 2005 to 2021, we compared the prevalence of irAEs using diagnosis codes and AC models, which classify drug-irAE pairs in clinical notes with implied textual causality. Four illustrative irAEs with high patient impact—myocarditis, encephalitis, pneumonitis, and severe cutaneous adverse reactions, abbreviated as MEPS—were analyzed using corticosteroid administration and ICI discontinuation as proxies of severity. RESULTS: For MEPS, only 70% (n = 118) of patients found by AC were also identified by diagnosis codes. Using AC models, patients with MEPS received corticosteroids for their respective irAE 82% of the time and permanently discontinued the ICI because of the irAE 35.9% (n = 115) of the time. CONCLUSION: Overall, AC models enabled more accurate identification and assessment of patient impact of ICI-induced irAEs not found using diagnosis codes, demonstrating a novel and more efficient strategy to assess real-world clinical outcomes in patients treated with ICIs.

18 April 2013 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
GCGeoff Culshaw
Geoff Culshaw
TWT. Wagner
T. Wagner
VFVirginia Luis Fuentes
Virginia Luis Fuentes
TST. Schwarz
T. Schwarz
DYD.A. Yool
D.A. Yool
DBD.J. Brockman
D.J. Brockman

1 January 2026 in The Breast Journal
Verified
Journal Article
Open access
AIAnushree R. Iyengar
Anushree R. Iyengar
EDErinn P. Downs
Erinn P. Downs
SMSandhya Mehta
Sandhya Mehta
NRNivedita Rangarajan
Nivedita Rangarajan
MWMichele Sue-Ann Woo
Michele Sue-Ann Woo
HBHannah Barman
Hannah Barman
Historically, HER2 status in invasive breast cancer has been categorized as HER2‐positive (IHC 3+, IHC 2+/ISH+) or HER2‐negative (IHC 0, IHC 1+, IHC 2+/ISH‐). Patients meeting IHC 0 with membrane staining (HER2‐ultralow) criteria may benefit from HER2‐targeted therapies such as trastuzumab deruxtecan. This cohort study assessed the prevalence of HER2‐ultralow expression by re‐scoring HER2 IHC slides using Mayo Clinic electronic health record data. Three hundred patients with advanced breast cancer (Stages III‐IV) and documented HER2 IHC 0 status (January 2017–March 2023) were identified. One slide per patient was digitized and independently re‐scored by two Mayo Clinic pathologists following the 2023 ASCO‐CAP guidelines, including tumor staining percentage to denote HER2‐ultralow status. A sensitivity analysis was performed by a third independent pathologist. The re‐scored patients had a mean age of 57.7 years (SD = 13.6). Most samples (95%, n = 285) remained scored IHC 0 by at least one pathologist; 60% of these met HER2‐ultralow criteria per at least one pathologist. HER2‐ultralow prevalence ranged from 43% to 45% per pathologist, with 57% overall interpathologist concordance. Samples with no observable staining comprised most of the concordant cases. Treatment patterns were similar between HER2‐ultralow and no‐staining groups; however, time to treatment failure (TTF) varied between groups across lines of therapy (LOT). In HR− positive cohorts, median TTF for LOT1 was 7.73 months in patients with HER2‐ultralow versus 9.43 months with no observable IHC staining. In HR− negative cohorts, median TTF was 5.00 months for HER2‐ultralow versus 3.17 months with no observable IHC staining. Similar TTF trends were observed in LOT2‐LOT3. Approximately three in five samples originally classified as IHC 0 met HER2‐ultralow criteria, suggesting many patients may benefit from HER2‐directed therapy if reclassified. These findings highlight potential challenges of identifying HER2‐ultralow expression and suggest the need for enhanced pathologist training, adherence to best practices, and integration of digital pathology and artificial intelligence solutions. Trial Registration: ClinicalTrials.gov_identifier: NCT03734029

1 April 2026 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
HDHilary DuBrock
Hilary DuBrock
XTXiaoqin Tang
Xiaoqin Tang
GDGurinderpal Doad
Gurinderpal Doad
JLJenny Lam
Jenny Lam
MCMichelle Cho
Michelle Cho
TWTyler E. Wagner
Tyler E. Wagner
Clinical worsening events are increasingly recognized as a meaningful outcome in pulmonary arterial hypertension (PAH). We applied machine‐learning models to real‐world data to identify clinical features that may predict clinical worsening events in PAH. Data were obtained retrospectively from the electronic health records of adults diagnosed with PAH at Mayo Clinic locations (January 2015–December 2019). Machine‐learning LASSO regularized logistic regression models were developed to analyze the association between 100 clinical features and occurrence of clinical worsening events. In total, 455 patients were included (mean age 62.1 years; 59.3% female). Of these, 232 (51.0%) experienced a clinical worsening event after a median (quartile 1, quartile 3) of 10.9 (4.1, 21.4) months. The best‐performing model had an area under the curve of 0.78, sensitivity of 78%, and specificity of 59%. The model identified 11 clinical features associated with clinical worsening events in PAH with a non‐zero coefficient: baseline age, body mass index (BMI), creatinine level, red cell (erythrocyte) distribution width (RDW), mean pulmonary arterial pressure, pulmonary vascular resistance, sodium concentration, and QT interval, along with dyspnea, number of clinic visits, and other forms of heart disease within a 1‐month window before a clinical worsening event. Baseline RDW and BMI, and number of clinic visits within the 1‐month window were statistically significantly associated with clinical worsening events. Our study used machine‐learning models to identify clinical features associated with risk of clinical worsening events in PAH. Automation of risk prediction could lead to earlier therapeutic intervention to optimize patient outcomes.